Efficacy and safety of tamsulosin in the treatment of urological diseases

Bibliography

• CARBON C: Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage. Eur. Microbial Infect. Dis. (1990) 9:510–516.
   PubMed Web of Science ®Google Scholar
• BERGOGNE-BEREZIN E: Predicting the efficacy of antimicrobial agents in respiratory infections: is tissue concentration a valid measure?' Antimicrob. Chemother. (1995) 35:363–371.
   Google Scholar
• NIX DE: Intrapulmonary concentrations of antimicrobial agents. Infect. Dis. North Am. (1998) 12:631–646.
   PubMed Web of Science ®Google Scholar
• HONEYBOURNE D, BALDWIN DR: The site concentrations of antimicrobial agents in the lung. I Antimicrob. Chemother. (1992) 30:249–260.
   PubMed Web of Science ®Google Scholar
• HONEYBOURNE D: Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curt: Opin. Palm. Med. (1997) 3:170–174.
   PubMedGoogle Scholar
• BERGOGNE-BEREZIN E: New concepts in the pulmonary disposition of antibiotics. Palm. Pharmacy]. (1995) 8:65–81.
   Google Scholar
• BARZA M: Tissue-directed antibiotic therapy: antibiotic dynamics in cells and tissue. Challenges to antibiotic activity in tissue. Clio. Infect. Dis. (1994) 19:910–915.
   PubMed Web of Science ®Google Scholar
• NIX DE, GOODWIN SD, PELOQUIN CA, ROTELLA DL, SCHENTAG JJ: Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob. Agents. Chemother. (1991) 35:1947–1952.
   PubMed Web of Science ®Google Scholar
• EMMERSON AM: The clinical significance of tissue concentrations. Res. Clio. Forums (1990) 12:117–121.
   Google Scholar
• DRUSANO GL: Role of pharmacolkinetics in outcome of infections. Antimicrob. Agents. Chemother. (1988) 32:289–297.
   PubMed Web of Science ®Google Scholar
• DE LOUVOIS J: Factors influencing the assay of antimicrobial drugs in clinical samples. Antimicrob. Chemother. (1982) 9:253–265.
   Google Scholar
• JEHL F: High performance liquid chromatography of antibiotics. JChromatogr: (1990) 531:509–548.
   PubMedGoogle Scholar
• JELLIFFE R, SCHUMITZKY A, VAN GUILDER M et a/.: Individualizing drug dosage regimen: role of population pharmacolkinetic models, bayesian fitting, and adaptive control. Therap. Drug Monk (1993) 15:390–393.
   Google Scholar
• BOUVIER D'YVOIRE MJY, MAIRE PAH: Dosage regimens of antibacterials: implications of pharmacokinetics/pharmacodynamic model. Therap. Drug Monit. (1996) 11:229–239.
   Google Scholar
• SCHENTAG JJ: Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with Gram-negative pneumonia. Scand. j Infect. Dis. (1991) 74(Suppl.):218–234.
   Google Scholar
• CRAIG WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin. Infect. Dis. (1998) 26:1–12.
   PubMed Web of Science ®Google Scholar
• PHAM LH, BRUN-BUISSON C, LEGRAND P et al.: Diagnosis of nosocomial pneumonia in mechanically ventilated patients. Comparison of a plugged telescoping catheter with the protected specimen brush. Am. Rev Respic Dis. (1991) 143:1055–1061.
   Google Scholar
• BALDWIN DR, WISE R, ANDREWS JM et al.: Microlavage: a technique for determining the volume of epithelial lining fluid. Thorax (1991) 46:658–662.
   PubMed Web of Science ®Google Scholar
• MEYERS BM, WILKINSON P: Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage. Clin. Pharmacokinet. (1989) 17:385–395.
   PubMed Web of Science ®Google Scholar
• SINGLAS E: Bases pharmacocinétiques de l'adaptation posologique chez finsuffisant renal chronique. In: Setninaire clam-nephrologie. Pitie-Salpetrierd Chatelain C, Jacobs C (Eds), Masson, Paris, France (1993):102–111.
   Google Scholar
• KOSCOVE EM: Sepsis and septic shock. In: Infectious diseases in emergency medicine (2'd edit). Brillman JC, Quenzer RW (Eds), Lippincott, Raven Publishers, USA (1997):129–152.
   Google Scholar
• CHARTRAND SA, MARKS MI: Pulmonary infections in cystic fibrosis: pathogenesis and therapy. In: Respiratory infections: diagnosis and management. Pennington JE (Ed.), Raven Press, New York, USA (1988):267–297.
   Google Scholar
• MENDELMAN PM, SMITH AL, LEVY J, WEBER A, RAMSEY B, DAVIS RL: Aminoglycoside penetration, inactivation and efficacy in cystic fibrosis sputum. Am. Rev Respir. Dis (1985) 132:761–765.
   PubMed Web of Science ®Google Scholar
• ROUSSEY M, HUSSON MO, HUET F:36.Current concepts in cystic fibrosis: pathogenesis, microbiology, new therapeutic approaches. Antibiotiques (2002) 4:203–224.
   Google Scholar
• REBUCK AS, BRAUDE AC: Assessment of drug disposition in the lung.37.Drugs (1984) 28:544–553.
   PubMed Web of Science ®Google Scholar
• VALCKE Y, PAUWELS R, VAN DER STRETEN M: Pharmacokinetics of antibiotics in the lungs. Eur. Respir. J. (1990) 3:715-722.38.
   PubMedGoogle Scholar
• RAOULT D, BROUQUI P: Intracellular location of microorganisms. In: Antimicrobial agents and intracellular39.Pathogens. Raoult D (Ed.), CRC Press, London, UK (1993):39–61.
   Google Scholar
• VALLEE E, AZOULAY-DUPUIS E, POCIDALO JJ, BERGOGNE-BEREZIN E:40.Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. Antimicrob. Agents Chemother (1992) 36:1412–1417.
   Google Scholar
• VALLEE E, AZOULAY-DUPUIS E,41.POCIDALO JJ, BERGOGNE-BEREZIN E: Pharmacokinetics of four fluoroquinolones in a mouse model of infected lung.' Antimicrob. Chemother. (1991) 28(Suppl. C):39–44.
   Google Scholar
• ZAK 0, O'REILLY T: Animal models in42.the evaluation of antimicrobial agents. Antimicrob. Agents Chemother. (1991) 35:1527–1531.
   Google Scholar
• FOULDS G, SHEPARD RM, JOHNSON RB: The pharmacokinetics of azithromycin in human serum and tissues. Antimicrob. Chemother. (1990) 25 (Suppl. A):73–82.
   Google Scholar
• MARLIN GE, BURGESS KR, BURGOYNE J, FUNNELL GR, GUINNESS MDG: Penetration of piperacillin into bronchial mucosa and sputum. Thorax (1981) 36:774–780.
   PubMed Web of Science ®Google Scholar
• BRUN Y, FOREY F, GAMONDES JP: Levels of erythromycin in pulmonary tissue and bronchial mucus compared to those of amoxycillin. Antimicrob. Chemother: (1981) 8:459–466.
   Google Scholar
• FRASCHINI F, SCAGLIONE F, PINTUCCI G, MACCARINELLI G, DUGNANI S, DEMARTINI G: The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. I Antimicrob. Chemother: (1991) 27(Suppl. A):61–65.
   Google Scholar
• BERGOGNE-BEREZIN E: Tissue distribution of dirithromycin: comparison with erythromycin. J. Antimicrob. Chemother: (1993) 31 (Suppl. C):77–87.
   Google Scholar
• BALDWIN DR, HONEYBOURNE D, WISE R: Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob. Agents Chemother: (1992) 36:1171–1175.
   PubMed Web of Science ®Google Scholar
• PANTEIX G, HARF R, DESNOTTES JF: Accumulation of pefloxacin in the lower respiratory tract demonstrated by bronchoalveolar lavage. Antimicrob. Chemother: (1994) 33:979–985.
   Google Scholar
• BRYSKIER A: Therapeutic alternatives in respiratory tract infections: contribution of levofloxacin. Antibiotiques (2000) 2:35–51.
   Google Scholar
• LABRO MT: Interaction between antimicrobial drugs and phagocytes: an overview. Int. I Antimicrob. Agents (1993) 3:73–87.
   PubMedGoogle Scholar
• ROHWEDDER R: Tissue penetration of ciprofloxacin with special reference to the lung. In: Ciprofloxacin in pulmonology Fass RJ (Ed.), W. Zuckschwerdt Verlag, Munchen, Germany (1990):67–77.
   Google Scholar
• CRAIG WA: Interrelationships between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum-cephalosporins. Diagn. Microbial. Infect. Dis. (1995) 22:89–96.
   PubMed Web of Science ®Google Scholar
• SCAGLIONE F., MOUTON JW, MATTINA R: Pharmacodynamics of levofloxacin in a murine pneumonia model: importance of peak to MIC ratio versus AUC. In: Progam and Abstracts of the 39-h Interscience Conference on Antimicrobial Agents M Chemotherapy San Francisco, USA, September 26–29 (1999) (Abstract 20).
   Google Scholar
• ROOSENDAAL R, BAKKER-WOUDENBER IA: Impact of the antibiotic dosage schedule on efficacy in experimental lung infections. Scand. Infect. Dis. (1991) 74(Suppl.):155–162.
   Google Scholar
• FIRSOV A, ZINNER S, LUBENHKO I et al.: Prediction of the equivalent fluoroquinolone (FQ) AUC/MIC breakpoints (BPs) based on pharmacodynamic studies with in vitro dynamic models: in vitro - in vivo correlations. In: Progam and Abstracts of the 39-h Interscience Conference on Antimicrobial Agents M Chemotherapy San Francisco, USA, September 26–29 (1999) (Abstract 24).
   Google Scholar
• RODRIGUEZ-CERRATO V, MICHELOW IC, GHAFFAR F et al.: Pharmacodynamics and bactericidal activity of Moxifloxacin in experimental E. coli meningitis. In: Progam and Abstracts of the 39-h Interscience Conference on Antimicrobial Agents in Chemotherapy, San Francisco, USA, Septemeber 26 — 29 (1999) (Abstract 29).
   Google Scholar
• VOSTROV S, LUBENKO I, KONONENKI 0 et al.: Comparative pharmacodynamics of gemifloxacin and ciprofloxacin with Saphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. In: Progarn and Abstracts of the 39h Interscience Conference on Antimicrobial Agents in Chemotherapy San Francisco, USA, Septemeber 26 — 29 (1999) (Abstract 26).
   Google Scholar
• LEGGETT JE, FANTIN B, EBERT S et al.: Comparative antibiotic dose-effects relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. (1989) 159:281–292.
   PubMed Web of Science ®Google Scholar
• ROOSENDAL R, BAKKER-WOUNDENBERG IAJM, VAN DEN BERG JC et al.: Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental K. pneumoniae pneumonia in rats. I Infect. Dis. (1985) 152:281–292.
   Google Scholar
• HOULIHAN HH, MERCIER RC, MACKINNON PS et al.: Vontinuous infusion versus intermitent administration of ceftazidime in critically ill patients with Gram-negative infection. 37h Interscience Conference on Antimicrobial Agents M Chemotherapy.. Toronto, Canada (1997) (Abstract A–42).
   Google Scholar
• VINKS A, BRIMICOMBE RW, HEIJERMAN HGM: Continuous infusion of cefatzidime in adults cystic fibrosis patients during continuous infusion and ambulatory treatment at home: clinical outcome, microbiology and pharmacolkinetics. Antimicrob. Chemother. (1997) 40:125–133.
   Google Scholar
• BOSELLI E, BREIHL D, DUFLO F et al:Steady state plasma and intraplmonary concentrations of cefepime administered in cntinuous infusion in critically ill patients with severe nosocomila pneumonia. Grit. Care Med. (2003) 31:2102–2106.
   PubMed Web of Science ®Google Scholar
• POWEL SH, THOMPSON WL, LUTHE MA et al.: Once daily versus continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamycin, tobramycin and netilmicin. J. Infect. Dis. (1983) 147:918–932.
   PubMed Web of Science ®Google Scholar
• ELLNER PD, NEU HC: The inhibitoryquotient. A method for interpreting minimum inhibitory concentration data. J. Am. Med. Assoc. (1981) 246:1575–1578.
   Google Scholar